commendations:

1. Only screen informed, asymptomatic men with a life expectancy greater than 10 years (shared decision-making is essential) Journals.co.za.
2. Do not screen:
   • Men over 70 years old, unless they’re in excellent health and fully informed (screening may still be considered) Journals.co.za.
   • Men with life expectancy under 10 years Journals.co.za.
3. PSA blood test is the first-line screening tool. Digital rectal exams (DREs) are not recommended routinely for asymptomatic men due to lack of added benefit Journals.co.za.
4. High-risk groups should begin screening earlier:
   • All men from age 50.
   • Black African men and those with a family history (prostate or breast cancer in a first-degree relative), from age 45.
   • Men with BRCA1/2, HOXB13, ATM, or CHEK2 gene mutations should start at 40, or 10 years younger than the youngest affected relative Journals.co.za.
5. Screening intervals should be individualized—some guidelines allow up to 8 years between tests, but more frequent testing may be justified in Black African men due to higher risk Journals.co.za.
6. Pause screening if recent events may raise PSA temporarily:
   • Acute prostatitis, urinary retention, urethral instrumentation, or recent prostate surgery—defer by 6–8 weeks Journals.co.za.
7. Repeat PSA if elevated but <10 ng/mL (“grey zone”) and DRE is normal. Abstain from ejaculation or cycling for ≥48 hours before repeat testing Journals.co.za.
8. Use free/total PSA ratio for added specificity when total PSA is in the grey zone:
   • ≤10% ratio = >80% cancer probability.
   • ≥25% ratio = <10% cancer probability Journals.co.za.
9. Adjust PSA level for men on 5-alpha-reductase inhibitors (finasteride or dutasteride): multiply PSA by 2 Journals.co.za.
10. Do not prescribe antibiotics or alpha-blockers to lower PSA in asymptomatic men without infection Journals.co.za.
11. Refer to a urologist when PSA remains persistently elevated (age-adjusted) or DRE is abnormal. In resource‐limited settings, very high PSA (e.g., >50 ng/mL) may suggest metastatic disease and prompt treatment even without biopsy Journals.co.za.

Summary Table:

Group / Situation	Guideline
Asymptomatic, informed, life > 10 yrs	Offer PSA screening
Age > 70 or life < 10 yrs	Do not screen generally
High-risk (Black, family history)	Start from age 45
Genetic mutation carriers	Start from age 40 (or 10 yrs younger than young relative)
Elevated PSA (<10 ng/mL)	Repeat test after abstinence; consider free/total ratio
On 5-ARI therapy	Adjust PSA by doubling
Suspicious results / high PSA	Refer to urologist; possible immediate treatment

---

Additional Context: Prostate Screening Practices in South Africa

Beyond formal guidelines, local health authorities and organizations highlight early detection and awareness:

• Western Cape Health Department encourages annual screening for men aged 50+, especially with family history, aligning with the National Integrated Men’s Health Strategy 2020–2025 Western Cape Government.
• The Prostate Cancer Foundation of South Africa advises:
  • All men over 45 get screened annually.
  • High-risk men (Black or family history) start at age 40 yeswecare.co.za.
• Community efforts like workshops and PSA drives (e.g., outreach by The Urology Hospital in Pretoria) are happening during Men’s Health Month, emphasizing early screening, particularly for men 45+ with family history urology.co.za.

---

Your Action Plan (Johannesburg Context)

1. If you or someone you know is considering prostate screening:
   • Have an informed discussion with a healthcare provider about the risks and benefits.
   • If asymptomatic, consider PSA testing in line with age and risk profile.
   • Proceed with the PSA test alone unless DRE is clinically indicated.
   • Interpret results appropriately:
     • If PSA is “grey zone” (e.g., 4–10 ng/mL), consider repetition and free/total PSA evaluation.
     • Adjust PSA if the person is on finasteride or dutasteride.
2. Encourage awareness:
   • Share with families and communities, especially Black men, about earlier and regular screening given higher local risk.
   • Support community health efforts like workshops or screenings during awareness months.
3. Engage your healthcare provider:
   • Use shared decision-making tools.
   • Personalized screening intervals based on prostate risk factors and baseline PSA levels.

---

Let me know if you’d like to explore:

• Specific Johannesburg-based screening programs or clinics offering PSA testing.
• Tools or pamphlets for patient education on prostate health.
• How to facilitate informed decision-making in clinics or community settings.

Happy to help further!